中药新方"斑晓胶囊"祛除"腑中之痰浊"抗动脉粥样硬化的机制研究

Atherosclerosis is the leading cause of cardiovascular events. The main pathological manifestation of atherosclerosis which belong to reversibility category mostly is soft plaque containing lipid. However, its mechanism is unclear and there is no effective therapeutic method. According to traditional Chinese medicine, atherosclerosis mainly lies in two aspects of deficiency in origin and enrichment in symptom: on one hand the phlegm obstructs blood vessels, on the other hand the nutrient-blood is in stasis, as time goes by the phlegm and nutrient-blood clump together. Because of traditional Chinese medicine theory, we product new traditional Chinese medicine "Banxiao capsule" to enhancing atherosclerosis regression. Based on preliminary studies, we are sure that "Banxiao capsule" can control and prevent the development of plaque, but the biology molecular mechanism is still unclear. According to the Chinese medicine theory of "if excess diminish it,if stasis clear it", "Banxiao capsule" enhance the regression of atherosclerosis based of diminish the excess and clear the stasis. The enterohepatic circulation of bile acid plays a crucial role in the homeostasis of blood fat and hence be an important factor contributed to the development of atherosclerosis. We set up the mice hyperlipidemia model then treat the mice with statins and "Banxiao capsule", and explore the viscera mechanism on treating atherosclerosis by "Banxiao capsule", for future clinical treatment of Chinese traditional medicine discovery and development.

动脉粥样硬化（AS）易损斑块是急性心脑血管事件的首要病因，主要病理表现 为富含炎症脂质的软斑块，是可逆性病变，但目前尚缺乏稳定和消退的有效措施。中医认为 AS 属痰瘀互结证，痰浊滞塞脉络，日久营血瘀滞，形成痰浊瘀血相凝之结块。据此我们配出中药新方"斑晓胶囊"并经过前期实验证实能有效控制AS 的发展，其对血管细胞及分子的作用机制已在研究中；已知肠道及肝脏中胆汁酸肠肝循环为胆固醇代谢的重要环节，从而对AS的形成和发展及控制起到关键作用，我们根据前期实验结果推测"斑晓胶囊"抗AS 机制不仅限于对血管粥样硬化斑块部位"痰浊"的作用，亦包括对脏腑中"痰浊"的祛除作用。我们应用高脂血症动物模型，分别给予他汀和斑晓干预，就肝肠中的胆酸肠肝循环的改变等进行研究，以探讨斑晓控制AS 的脏腑机制，为临床中医药防治心脑血管疾病提供新方法和新策略。

动脉粥样硬化(AS)易损斑块是急性心脑血管事件的首要病因，主要病理表现 为富含炎 症脂质的软斑块，是可逆性病变，但目前尚缺乏稳定和消退的有效措施。中医认为 AS 属 痰瘀互结证，痰浊滞塞脉络，日久营血瘀滞，形成痰浊瘀血相凝之结块。据此我们配出中药新方"斑晓胶囊"并经过前期实验证实能有效控制AS的发展，其对血管细胞及分子的作用机制已在研究中;已知肠道及肝脏中胆汁酸肠肝循环为胆固醇代谢的重要环节，从而对 AS的形成和发展及控制起到关键作用，我们根据前期实验结果推测"斑晓胶囊"抗AS的机制不仅限于对血管粥样硬化斑块部位"痰浊"的作用，亦包括对脏腑中"痰浊"的祛除作用。基于高脂血症动物模型和体外caco-2细胞模型，分别给予他汀和斑晓干预，发现：与他汀不同，复方中药主要可通过调节胆酸肠肝循环改善血脂，同时可抑制代谢异常导致的肠道黏膜屏障功能受损，相关研究将为临床中医药防治心脑血管疾病提供新方法和新策略。